Cimicifugoside

• UNSPSC Description:

  Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity[1]. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function[2].

• Target Antigen:

  Others

• Type:

  Natural Products

• Related Pathways:

  Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cimicifugoside.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@H]([C@H]([C@@H](CO1)O)O)[C@@H]1O[C@@H]2CC[C@]3(C4)C54C[C@H](OC(C)=O)[C@]6(C)[C@@H]([C@H](C)C[C@@]7(O8)[C@@](O9)([H])[C@@]9(C)C8O)[C@](O7)([H])C[C@](C)6C5=CC[C@]([H])3C2(C)C

• Molecular Weight:

  674.82

• References & Citations:

  [1]Yawata A, et al. Inhibition of nucleoside transport and synergistic potentiation of methotrexate cytotoxicity by cimicifugoside, a triterpenoid from Cimicifuga simplex. Eur J Pharm Sci. 2009 Nov 5;38(4):355-61.|[2]Hemmi H, et al. The immune response of splenic lymphocytes after cimicifugoside treatment in vitro and pretreatment in vivo. J Pharmacobiodyn. 1980 Dec;3(12):643-8.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  66176-93-0